News

Surgery can usually be avoided in children with a rare tumor of the skull, based on new research by investigators from Weill Cornell Medicine, NewYork-Presbyterian, Nicklaus Children’s Hospital, the University of Texas Southwestern, the University of British Columbia and McGovern Medical School.    

Improvements in trauma care could save the lives of thousands of people injured in road traffic accidents in low- and middle-income countries annually, according to a study led by a Weill Cornell Medicine and NewYork-Presbyterian investigator.

Weill Cornell Medicine, Rutgers Cancer Institute of New Jersey and Cold Spring Harbor Laboratory have received a $25 million Cancer Grand Challenges award to tackle cancer cachexia, the debilitating wasting syndrome that is responsible for up to 30 percent of cancer-related deaths.

A large clinical trial among people living with HIV has found that treating anal precancerous lesions cuts the risk of developing anal cancer by 57 percent compared with active monitoring with no treatment.

A new onset of a rapid or irregular heartbeat that develops after surgery, often within a few days, is associated with an increased risk for hospitalization for heart failure among patients undergoing both cardiac and noncardiac surgery, according to a new study by Weill Cornell Medicine and NewYork-Presbyterian investigators.

There is considerable variation in the management of mantle cell lymphoma across different clinical settings, and some strategies do not always conform with what might be expected, according to an analysis by investigators from Weill Cornell Medicine and other leading health institutions.

Weill Cornell Medicine and New York Genome Center researchers, in collaboration with Oxford Nanopore Technologies, have developed a new method to assess on a large scale the three-dimensional structure of the human genome, or how the genome folds.

Dr. Laura Alonso, chief of the Division of Endocrinology, Diabetes and Metabolism and the Herbert J. and Ann L. Siegel Distinguished Professor of Medicine at Weill Cornell Medicine, has been selected to be a fellow of the Hedwig van Ameringen Executive Leadership in Academic Medicine (ELAM) Program at Drexel University College of Medicine.

Dr. Sheila Nirenberg, the Nanette Laitman Professor of Neurology and Neuroscience and a professor of physiology and biophysics at Weill Cornell Medicine, has received the Barbara McClintock Women Innovator Award at the Inaugural Women Innovator Awards.

A multidisciplinary research program launched by Weill Cornell Medicine, the ILR School and Cornell Tech aims to elevate the value of home care workers while improving both their working conditions and their patients’ outcomes. 

A recent Pfizer or Moderna mRNA-vaccine booster provided good but temporary protection against infection by the SARS-CoV-2 omicron variant.

A new preclinical study by Weill Cornell Medicine investigators shows that one specific set of antibodies that is induced naturally by gut beneficial bacteria can be transferred from mothers to infants through breast milk and help infants defend against infection-induced diarrheal illness.

A class of proteins known as TMEM16 scramblases permit rearrangement of lipids in the cell membrane chiefly by...

Dr. Sara Zaccara, a postdoctoral associate in the Department of Pharmacology at Weill Cornell Medicine, has won a 2022 Tri-Institutional Breakout Award for Junior Investigators.

A promising venture that hopes to develop a new drug therapy for colorectal cancer won $50,000 in funding and recognition from experienced venture capitalists on May 26 at the annual Biomedical Business Plan Challenge.

Genetically engineered immune cells successfully target the specific cancer cells that may be responsible for relapse of acute myeloid leukemia, a type of blood cancer, and proved effective in animal models of the disease.

Awards, honors, prizes and achievements for the month of May. 

SARS-CoV-2 infections of women in late pregnancy frequently spread to their placentas and led to inflammation.

Researchers at Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center have identified a previously unrecognized form of hormone therapy-resistant prostate cancer, as well as a set of molecules that drive its growth. This discovery opens the door to the development of therapies that treat this specific disease.

Mutations that drive cancer growth also make a cell more noticeable to the immune system, according to a study by investigators at Weill Cornell Medicine, Weill Cornell Graduate School of Medical Sciences and Memorial Sloan Kettering Cancer Center.